First Time Loading...

Beijing Strong Biotechnologies Inc
SZSE:300406

Watchlist Manager
Beijing Strong Biotechnologies Inc Logo
Beijing Strong Biotechnologies Inc
SZSE:300406
Watchlist
Price: 18.49 CNY 4.17% Market Closed
Updated: Apr 29, 2024

Beijing Strong Biotechnologies Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Beijing Strong Biotechnologies Inc
Cash from Operating Activities Peer Comparison

Comparables:
6160
1801
603392
300122
300896

Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Beijing Strong Biotechnologies Inc
SZSE:300406
Cash from Operating Activities
¥585.1m
CAGR 3-Years
68%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cash from Operating Activities
-¥7.8B
CAGR 3-Years
-12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Cash from Operating Activities
-¥1.7B
CAGR 3-Years
-78%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash from Operating Activities
¥1.5B
CAGR 3-Years
49%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cash from Operating Activities
¥3.6B
CAGR 3-Years
3%
CAGR 5-Years
106%
CAGR 10-Years
47%
Imeik Technology Development Co Ltd
SZSE:300896
Cash from Operating Activities
¥1.2B
CAGR 3-Years
57%
CAGR 5-Years
70%
CAGR 10-Years
N/A

See Also

What is Beijing Strong Biotechnologies Inc's Cash from Operating Activities?
Cash from Operating Activities
585.1m CNY

Based on the financial report for Dec 31, 2023, Beijing Strong Biotechnologies Inc's Cash from Operating Activities amounts to 585.1m CNY.

What is Beijing Strong Biotechnologies Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
18%

Over the last year, the Cash from Operating Activities growth was 48%. The average annual Cash from Operating Activities growth rates for Beijing Strong Biotechnologies Inc have been 68% over the past three years , 18% over the past five years .